PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Fostair NEXThaler (beclometasone and formoterol) - Asthma

PAD Profile : Fostair NEXThaler (beclometasone and formoterol) - Asthma

Keywords :
ICS LABAs, ICS/LABAs, inhaled corticosteroids, long-acting beta agonists, respiratory, asthmatics, MART action plans, maintenance and reliever therapy
Brand Names Include :
Fostair NEXThaler

Traffic Light Status

Status 1 of 1.

Status :
Green
Important
Formulations :
  • Inhaler (dry powder)
Important Information :
Not licensed in under 18s
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 March 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Fostair® (beclometasone / formoterol) metered dose inhaler is the locally preferred ICS/LABA.
Fostair Nexthaler ® breath-actuated inhaler is the preferred dry powder ICS/LABA device.

It is licensed for Maintenance and Reliever Therapy (MART) and is available in a full range of doses. See MART action plan document below.

Fostair devices are not licensed in under 18's.

Prescribe inhaler devices by BRAND to ensure consistency and avoid confusion.

See Asthma Guidelines below.

Associated BNF Codes

03. Respiratory System
03.02.00. Corticosteroids (respiratory)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More